Wayne Greaves - Concepedia

Author

Wayne Greaves

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

W Greaves, W L Greaves, W. Greaves, W. L. Greaves, WAYNE GREAVES, WAYNE L. GREAVES, Wayne Greaves, Wayne L. Greaves, Wayne L. Greaves

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Harvard University Brigham and Women's Hospital Johns Hopkins University Cornell University

About

Wayne Greaves is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, infection control, and hiv.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	1.7K
2	Epidemiology	7	7	1K
3	Public Health	2	2	225
4	Health Sciences	1	1	70
5	Allergy	1	1	13

Wayne Greaves

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study David Roth, David R. Nelson, Annette Bruchfeld, The Lancet Hepatic DisordersHepatitis CViral HepatitisChronic Kidney DiseaseCombination Phase 3	2015	663
Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211 Roy M. Gulick, Zhaohui Su, Charles Flexner, The Journal of Infectious Diseases	2007	239
Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo Athe Tsibris, Bette Korber, Ramy Arnaout, PLoS ONE	2009	224
HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211 Timothy Wilkin, Zhaohui Su, Daniel R. Kuritzkes, Clinical Infectious Diseases	2007	182
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial Mark Sulkowski, Stanislas Pol, Josep Mallolas, The Lancet Infectious Diseases Viral HepatitisImmunologyPegylated Interferon Alfa-2bHepatitisVirology	2013	180
A Multicenter Randomized Trial Evaluating Posaconazole versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects with HIV/AIDS José A. Vázquez, Daniel J. Skiest, Leonardo Nieto, Clinical Infectious Diseases	2006	172
CONGENITAL RUBELLA SYNDROME IN THE UNITED STATES, 1970–1985 Stephen L. Cochi, LARRY E. EDMONDS, Karen Dyer, American Journal of Epidemiology Thumb HypoplasiaNeonatologyCongenital Rubella SyndromeClinical EpidemiologyPediatrics	1989	123
In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject Athe Tsibris, Manish Sagar, Roy M. Gulick, Journal of Virology	2008	109
Pneumococcal Bacteremia in Adults: A 14-Year Experience in an Inner-City University Hospital Bekele Afessa, Wayne Greaves, Winston Frederick Clinical Infectious Diseases Pneumococcal VaccinationPneumococcal BacteremiaHospital MedicineHealthcare-associated InfectionClinical Epidemiology	1995	102
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial Margaret Johnson, Princy Kumar, Jean‐Michel Molina, JAIDS Journal of Acquired Immune Deficiency Syndromes	2019	92

Page 1